Passing of Genmab A/S' Annual General Meeting

Summary: At Genmab A/S' Annual General Meeting held today on April 19, 2007 the 
Annual Report for 2006 was approved, discharge was given to the Board of        
Directors and the Management and the year's loss was carried forward. One member
of the Board of Directors was re-elected and two new members were elected.      
PricewaterhouseCoopers was re-elected as auditor of the Company. The proposals  
from the Board of Directors to change the Articles of Association and           
authorization to allow the Company to purchase shares in the Company were       
adopted.                                                                        


Copenhagen, Denmark; April 19, 2007 - Genmab A/S (CSE: GEN) held its Annual     
General Meeting, today April 19, 2007 at 2:00 pm at Radisson SAS Royal Hotel,   
Hamerichsgade 1, 1611 Copenhagen, Denmark.                                      

At the meeting Chairman of the Board Dr. Michael B. Widmer gave - on behalf of  
the Board - a report on the Company's activities during the past year. Chief    
Executive Officer and member of the Board, Lisa N. Drakeman presented plans for 
the year ahead, and Chief Financial Officer Bo Kruse presented the Annual Report
for 2006 endorsed by the auditors. The report was approved and discharge was    
given to the Board and the Management.                                          

It was decided that the year's loss of DKK 438 million be carried forward by    
transfer to accumulated deficit, as stated in the Annual Report.                

Dr. Anders Gersel Pedersen was re-elected to the Board for a further three year 
period. Dr. Burton G. Malkiel and Hans Henrik Munch-Jensen were elected to the  
Board for a period of three and two years respectively.                         

PricewaterhouseCoopers (State Authorized Accountants) was reelected as the      
Company's auditor.                                                              

The General Meeting adopted the proposals from the Board to change the Company's
Articles of Association, as follows:                                            

- The proposal to amend Article 4A of the Articles of Association, authorizing 
the Board of Directors to issue new shares, so that the authorization is        
increased from nominally DKK 10,528,798 shares to nominally DKK 15,000,000      
shares and it is prolonged to apply for 5 years from this General Meeting, and  
so that within the 15,000,000 shares the Board may issue up to nominally DKK    
2,000,000 shares (including bonus shares) to employees of the Company and its   
subsidiaries.                                                                   

- The proposal to amend Article 6A to authorize the Board of Directors to issue 
additional warrants - without pre-emption rights for the existing shareholders -
that give the right to subscribe up to nominally DKK 1,000,000 shares in the    
Company to members of the Company's Board of Directors, the Company's employees 
and consultants as well as employees and consultants of the Company's           
subsidiaries and to implement the corresponding capital increases related to the
warrants issued.                                                                

- The proposal to amend Article 7 section one of the Articles of Association as
a consequence of VP Investor Service A/S's acquisition of the shareholder
registry activities from Danske Bank A/S. 

- The proposal to amend Article 9 section 4 of the Articles of Association as a 
consequence of a change of the Danish Companies Act under which it is required  
that callings for the Company's general meetings are published in the computer  
information system of the Danish Commerce and Companies Agency.                 

- The proposal to amend Article 18 of the Articles of Association to reflect
the Company's application of the current accounting regulations. 

Finally the Board of Directors were authorized according to Section 48 of the   
Danish Companies Act so that until the next Annual General Meeting the Company  
may purchase own shares in connection with the buy-back of shares subscribed by 
employees etc. pursuant to the Company's employee warrant programmes to the     
extent of up to 2 percent of the Company's share capital and so that the        
consideration for such shares shall be equal to the exercise price paid for the 
shares in question.                                                             


About Genmab A/S                                                                
Genmab A/S is a biotechnology company that creates and develops human antibodies
for the treatment of life-threatening and debilitating diseases. Genmab has     
numerous products in development to treat cancer, infectious disease, rheumatoid
arthritis and other inflammatory conditions, and intends to continue assembling 
a broad portfolio of new therapeutic products. At present, Genmab has multiple  
partnerships to gain access to disease targets and develop novel human          
antibodies including agreements with Roche and Amgen. A broad alliance provides 
Genmab with access to Medarex, Inc.'s array of proprietary technologies,        
including the UltiMAb(R) platform for the rapid creation and development of     
human antibodies to virtually any disease target. In addition, Genmab has       
developed UniBody(TM), a new proprietary technology that creates a stable,      
smaller antibody format.  Genmab has operations in Europe and the US. For more  
information about Genmab, visit www.genmab.com.                                 

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-EGFr(TM); 
HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM), HuMax-CD38(TM);
HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.                
UltiMAb(R) is a trademark of Medarex, Inc.                                      

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 15/2007